IRVINE, Calif., March 9, 2017 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that a district court in Düsseldorf, Germany ruled that Boston Scientific's Lotus valve infringes one of Edwards' patents for transcatheter aortic valves, but does not infringe a second. The court also ruled that the Edwards SAPIEN 3 valve infringes two of Boston Scientific's patents for outer seals of transcatheter heart valves. Edwards will promptly request an appeal, and believes that the company will ultimately prevail.
Boston Scientific initiated litigation that now involves multiple patents in multiple venues, and will likely yield court actions over an extended period of time. The company does not presently anticipate disruption to the supply of SAPIEN 3 valves to patients, and Edwards is not updating its 2017 financial guidance.
About Edwards Lifesciences
Edwards Lifesciences, based in Irvine, Calif., is the global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring. Driven by a passion to help patients, the company collaborates with the world's leading clinicians and researchers to address unmet healthcare needs, working to improve patient outcomes and enhance lives. For more information, visit www.Edwards.com and follow us on Twitter @EdwardsLifesci.
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements include, but are not limited to, statements regarding financial guidance and expected future impacts of the court's decision. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement.
Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those expressed or implied by the forward-looking statements based on a number of factors, including but not limited to, unanticipated outcomes from future appeals and legal proceedings, including potential damages, costs and injunctive relief (which is not automatic, but is instead up to each party to enforce), and the effectiveness of plans to mitigate these impacts. These factors are detailed in the company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2016. These filings, along with important safety information about our products, may be found at edwards.com.
Edwards, Edwards Lifesciences, the stylized E logo, SAPIEN and SAPIEN 3 are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/german-patent-court-issues-initial-decision-300421074.html
SOURCE Edwards Lifesciences Corporation